Originally published on: November 25, 2024
Decentralized science (DeSci) is on the brink of revolutionizing the scientific community, much like decentralized finance (DeFi) did in 2019. According to Andrew Kang, a founder and partner at Mechanism Capital, DeSci projects are currently in their experimental stage but hold tremendous potential for growth.
Kang believes that DeSci projects, such as BIO Protocol, Pump Science, and GLP1, are at the forefront of innovation in the field. BIO Protocol allows users to co-own “medicines of the future,” while Pump Science enables the trading of tokens tied to longevity medicines. On the other hand, GLP1 aims to “Make America Skinny Again” through its revolutionary approach.
At Mechanism Capital, Kang has already invested in BIO Protocol’s latest funding round, showcasing the firm’s belief in the future of DeSci. These projects utilize blockchain technology, tokens, NFTs, and decentralized autonomous organizations (DAOs) to incentivize scientific research and collaboration, ultimately aiming to address challenges in the peer review system and revolutionize healthcare solutions.
The rise of DeSci comes at a critical time as cybersecurity attacks on healthcare institutions are on the rise. By leveraging blockchain technology, DeSci can offer increased data accessibility to researchers and healthcare professionals while ensuring the security and transparency of sensitive information.
With a current market cap of $1.2 billion, DeSci is rapidly gaining traction, led by projects like OriginTrail (TRAC), Rifampicin (RIF), and VitaDAO (VITA). These projects are poised to reshape the future of scientific research and collaboration, offering new possibilities for innovation and discovery.
As the world continues to embrace blockchain technology, DeSci represents a new frontier in scientific exploration. Stay tuned as this innovative field evolves and unlocks new opportunities for scientific advancement. Discover the potential of DeSci and be part of the future of crypto.
